64Cu-MM-302 is being tested for its effectiveness against advanced HER2+ cancers with brain metastases (NCT02735798) (17), while 99mTc-labeled NM-02 is under investigation for breast cancer (NCT04040686) (16). This evidence concerns the gene ERBB2 and breast carcinoma.